Skip to content

Outcomes of Transrenal Artery Perfusion Versus Transrenal Vein Perfusion Using LifePort for Deceased Donor Kidney Transplantation

Outcomes of Transrenal Artery Perfusion Versus Transrenal Vein Perfusion Using LifePort for Deceased Donor Kidney Transplantation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04569682
Enrollment
108
Registered
2020-09-30
Start date
2020-01-01
Completion date
2022-12-30
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation, Organ Preservation

Brief summary

The main objective of this study is to compare the outcomes of transrenal artery perfusion versus transrenal vein perfusion using LifePort for deceased donor kidney transplantation. Patients registered in the National Dialysis and Transplant Registry awaiting deceased donor kidney transplantation were included. Delayed graft function (DGF) or primary nonfunction (PNF) may occur after deceased donor kidney transplantation. Compared with static cold storage, the application of LifePort can significantly reduce the incidence of DGF and PNF in deceased donor kidney transplantation. Transrenal artery perfusion is currently the mainstream but confronts multiple renal arteries, resulted in prolonged cold ischemia time. Transrenal vein perfusion is expected to be a solution. However, whether the clinical outcomes of transrenal vein perfusion is inferior to transrenal artery perfusion remains unknown. In this study, values of urine volume and creatinine, incidence and duration of DGF, and incidence of PNF within 1 week after surgery are recorded and compared between the transrenal artery perfusion group and the transrenal vein perfusion group. Monthly eGFR and creatinine values, the incidence of acute rejection within 1 year after transplantation and 1-year graft and patient survival are also recorded and compared.

Interventions

DEVICELifePort transrenal artery perfusion

transrenal artery perfusion group

DEVICELifePort transrenal vein perfusion

transrenal vein perfusion group

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Adult recipients older than 18 years; 2. Patients diagnosed with end-stage renal diseases and volunteered to register in the Transplant and Dialysis Registry of China awaiting for deceased donor kidney transplantation; 3. First single kidney transplantation; 4. The recipients can understand the purpose and risk of deceased kidney transplantation and sign informed consent; 5. Ethics committee approved.

Exclusion criteria

1. Patients less than 18 years old, or more than 65 years old; 2. Patients who receive multiple organ transplants; 3. Diagnosed with malignancy or had a history of malignancy in the past 5 years; 4. non-kidney transplantation history.

Design outcomes

Primary

MeasureTime frameDescription
Delayed graft functionWithin one week posttransplantationDelayed graft function is defined as the need for dialysis (for any cause) within the first week posttransplantation.

Secondary

MeasureTime frameDescription
Graft lossOne year after transplantationGraft loss was defined as re-establishment of long-term dialysis or estimated glomerular filtration rate (eGFR) of \<15 ml/min.
biopsy-confirmed acute rejectionOne year after transplantationbiopsy-confirmed acute rejection was diagnosed clinically based on a significant increase in serum creatinine levels of 50% or more within 3 days, which was not explained by other reasons and confirmed by biopsy.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026